Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

BACKGROUND: We analyzed the 96-week results in the overall population and in prespecified subgroups from the ongoing STARTMRK study of treatment-naive HIV-infected patients. METHODS: Eligible patients with HIV-1 RNA (vRNA) levels >5000 copies per milliliter and without baseline resistance to efav...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Acquir Immune Defic Syndr
Main Authors: Lennox, Jeffrey L., DeJesus, Edwin, Berger, Daniel S., Lazzarin, Adriano, Pollard, Richard B., Madruga, Jose Valdez Ramalho, Zhao, Jing, Wan, Hong, Gilbert, Christopher L., Teppler, Hedy, Rodgers, Anthony J., Barnard, Richard J. O., Miller, Michael D., DiNubile, Mark J., Nguyen, Bach-Yen, Leavitt, Randi, Sklar, Peter
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6065510/
https://ncbi.nlm.nih.gov/pubmed/20404738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0b013e3181da1287
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados